Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

iCMLf

iCMLf Prizes

Programs

Virtual Education Program

    Jerry Radich - Transplantation for CML in 2011: Who, why, when?

    Transplantation for CML in 2011: Who, why, when?

    Jerry Radich, Fred Hutchinson Cancer Research Center, Seattle, USA

    Please wait as the educational presentation will start automatically. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

     

    webcast-button
    vep jerryradich

    		 

    Issues covered

    • The role of transplantation in 2011
    • Who should be transplanted
    • When they should be transplanted
    • Why they should be transplanted

    Has this been helpful? Please provide your comments here:

    Facteur de variabilité de la réponse au ITK</li>
                  <li>Les trois grand mécanismes de résistance</li>
                  <li>La réponse au traitement</li>
                  <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib